d operating expenses", "adjusted SG&A expenses" and "adjusted operating income", which
exclude nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges;
"adjusted income from continuing operations", "adjusted diluted earnings per share from continuing operations" and "adjusted tax rate", which
exclude nonrecurring items primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items; and
"adjusted segment profit", which
excludes nonrecurring items primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges.
The most directly comparable measure for these non-GAAP financial measures are operating expenses, SG&A expenses, operating income, income from continuing operations, diluted earnings per share from continuing operations, tax rate, and segment profit (the most comparable GAAP measures). The company has included below unaudited adjusted financial information for the quarters ended Sept. 30, 2011 and 2010, which includes a reconciliation of GAAP to non-GAAP financial measures.
In addition, CareFusion presents the non-GAAP financial measure "adjusted diluted earnings per share" on a forward-looking basis. The most directly comparable forward-looking GAAP measure for the company is diluted earnings per share. CareFusion is unable to provide a quantitative reconciliation of this forward-looking non-GAAP financial measure to the most directly comparable forward-looking GAAP measure, because the company cannot reliably forecast restructuring and acquisition integration costs, and other nonrecurring costs. Please note that the unavailable reconciling items could significantly impact CareFusion's future financial results. A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful infor
'/>"/>
SOURCE CareFusion Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1.
ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation2.
Sequenom, Inc. Reports Financial Results for the Third Quarter of 20113.
InterMune Reports Third Quarter 2011 Financial Results and Business Highlights4.
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results5.
Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results6.
Caliper Life Sciences Reports Third Quarter 2011 Results7.
Neurocrine Biosciences Reports Third Quarter 2011 Results8.
United Therapeutics Corporation Reports Third Quarter 2011 Financial Results9.
Sangamo BioSciences Reports Third Quarter 2011 Financial Results10.
Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones11.
ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018